38 Combined cold and heat-induced cholinergic urticaria

1985 ◽  
Vol 75 (1) ◽  
pp. 114
Author(s):  
J FARNAM ◽  
J GRANT ◽  
R ALLEN ◽  
J JORIZZO ◽  
R LORD ◽  
...  
1989 ◽  
Vol 51 (6) ◽  
pp. 1106-1108 ◽  
Author(s):  
Kazunobu OTOYAMA ◽  
Yasuhiro HORIUCHI ◽  
Ryuji SAKAKIBARA ◽  
Toshio FUKUTAKE

2009 ◽  
Vol 102 (5) ◽  
pp. 416-421 ◽  
Author(s):  
Konstantinos Petalas ◽  
Kalliopi Kontou-Fili ◽  
Christina Gratziou

2019 ◽  
Vol 7 (4) ◽  
pp. 1355-1357.e1 ◽  
Author(s):  
Emilia Juliane Mellerowicz ◽  
Aida Asady ◽  
Marcus Maurer ◽  
Sabine Altrichter

2021 ◽  
Vol 24 (3) ◽  
pp. 211-226
Author(s):  
Elena Yu. Borzova ◽  
Christina Yu. Popova ◽  
Marcin Kurowski ◽  
Maia T. Rukhadze ◽  
Razvigor Darlenski ◽  
...  

Cholinergic urticaria (CholU) is a chronic inducible urticaria, characterised by itchy pinpoint wheals up to 3 mm in diameter, surrounded by a prominent flare, that occur following an exposure to characteristic triggers such as active or passive heating, physical exercise, emotions, hot or spicy foods. Key pathophysiologic mechanisms include immediate hypersensitivity to autologous sweat antigens, functional sweating disorders, impaired acethylcholine metabolism, abnormal skin vascular permeability and disturbed skin innervation. Clinical manifestations of CholU may vary from typical itchy pinpoint urticarial lesions, angioedema to anaphylaxis. Atypical CholU forms include cholinergic pruritus, cholinergic dermographism, cold cholinergic urticaria and persistent cholinergic erythema. The diagnosis of cholinergic urticaria relies on patients history, сlinical manifestations and challenge tests. Treatment options include nonsedating H1 antihistamines in standard or increased doses. The evidence is accumulating for the use of biological treatment with omalizumab in cholinergic urticaria. The prospect of personalized treatment of cholinergic urticaria include autologous sweat desensitization. The main research efforts in ColdU are directed at optimizing diagnostic approaches and developing innovative therapeutic options.


1978 ◽  
Vol 61 (3) ◽  
pp. 181
Author(s):  
R SIGLER ◽  
A LEVINSON ◽  
R EVANSIII ◽  
Z HORAKOVA ◽  
A KAPLAN

2003 ◽  
Vol 31 (6) ◽  
pp. 32-36 ◽  
Author(s):  
Tod M. Sweeney ◽  
William W. Dexter

1981 ◽  
Vol 68 (4) ◽  
pp. 319-324 ◽  
Author(s):  
A KAPLAN ◽  
S NATBONY ◽  
A TAWIL ◽  
L FRUCHTER ◽  
M FOSTER

Sign in / Sign up

Export Citation Format

Share Document